Windtree Therapeutics, Inc. (NASDAQ:WINT) Sees Significant Decrease in Short Interest

Windtree Therapeutics, Inc. (NASDAQ:WINT) saw a large decline in short interest in the month of August. As of August 31st, there was short interest totaling 331,500 shares, a decline of 70.8% from the August 15th total of 1,134,200 shares. Based on an average trading volume of 9,013,100 shares, the short-interest ratio is presently 0.0 days. Approximately 9.1% of the company’s stock are sold short. Approximately 9.1% of the company’s stock are sold short. Based on an average trading volume of 9,013,100 shares, the short-interest ratio is presently 0.0 days.

Windtree Therapeutics Trading Down 10.5%

Shares of WINT stock opened at $0.06 on Friday. The firm has a fifty day simple moving average of $0.52 and a two-hundred day simple moving average of $0.98. The firm has a market capitalization of $1.82 million, a PE ratio of 0.00 and a beta of 0.57. Windtree Therapeutics has a 12 month low of $0.06 and a 12 month high of $178.00.

Windtree Therapeutics (NASDAQ:WINT) last announced its earnings results on Tuesday, August 19th. The company reported ($3.06) EPS for the quarter, beating the consensus estimate of ($99.00) by $95.94. On average, equities analysts predict that Windtree Therapeutics will post -5.66 earnings per share for the current fiscal year.

About Windtree Therapeutics

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.